<DOC>
	<DOCNO>NCT00112931</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . It yet know whether rituximab effective observation treat non-Hodgkin 's lymphoma . PURPOSE : This randomized phase III trial study rituximab see well work compare observation treat patient newly diagnose stage II , stage III , stage IV follicular non-Hodgkin 's lymphoma symptom .</brief_summary>
	<brief_title>Rituximab Treating Patients With Newly Diagnosed Stage II , Stage III , Stage IV Follicular Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare time initiation systemic chemotherapy radiotherapy patient newly diagnose , previously untreated , asymptomatic stage II-IV non-bulky follicular non-Hodgkin 's lymphoma treat rituximab vs observation . Secondary - Compare frequency clinical spontaneous remission patient treat regimen . - Compare overall cause-specific survival patient treat regimen . - Determine effect rituximab complete partial response patient treat subsequent systemic chemotherapy . - Compare quality life , term functional well-being anxiety depression , patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center , disease grade ( 1 vs 2 v 3a ) , disease stage ( II v III v IV ) , age . Patients randomize 1 3 treatment arm . - Arm I : Patients undergo observation disease progression . - Arm II : Patients receive induction rituximab IV day 1 . Treatment repeat weekly 4 week . - Arm III : Patients receive induction rituximab arm II . Patients receive maintenance rituximab IV day 1 week 12 , 20 , 28 , 36 , 44 , 52 , 60 , 68 , 76 , 84 , 92 , 100 . In arm , treatment continue absence unacceptable toxicity disease progression require systemic chemotherapy* radiotherapy . NOTE : *Rituximab administration arm I consider initiation systemic chemotherapy Quality life assess baseline ( randomization ) , every 2 month 2 year , every 6 month 2 year . Patients follow every 2 month 2 year every 3 month thereafter . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : A total 600 patient ( 200 per treatment arm ) accrue study within 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm follicular nonHodgkin 's lymphoma Diagnosed within past 3 month Grade 1 , 2 , 3a disease Stage IIIV disease No evidence histological transformation Bidimensionally measurable disease clinical examination radiography Asymptomatic disease without B symptom severe pruritus Low tumor burden , define follow criterion : Lactic dehydrogenase normal Largest nodal extranodal mass &lt; 7 cm No 3 nodal site diameter &gt; 3 cm No clinically detectable significant serous effusion chest xray Clinically nonevident small effusion CT scan consider significant Spleen enlargement â‰¤ 16 cm CT scan Circulating tumor cell &lt; 5,000/mm^3 No organ compression ( i.e. , ureteric obstruction ) PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Life expectancy Not specify Hematopoietic Absolute neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Hemoglobin &gt; 10 g/dL Hepatic AST ALT normal Alkaline phosphatase normal Bilirubin normal Renal Creatinine &lt; 2 time upper limit normal ( unless due lymphoma ) Other Not pregnant nursing Fertile patient must use effective contraception 12 month completion rituximab No known HIV positivity No malignancy within past 2 year except curatively treat basal cell squamous cell skin cancer carcinoma situ cervix No critical organ failure No immediate lifethreatening disease PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other No prior therapy lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
</DOC>